180 related articles for article (PubMed ID: 17464871)
21. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus.
Pillai SK; Wennersten C; Venkataraman L; Eliopoulos GM; Moellering RC; Karchmer AW
Clin Infect Dis; 2009 Oct; 49(8):1169-74. PubMed ID: 19769538
[TBL] [Abstract][Full Text] [Related]
22. In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus.
Fritsche TR; Rhomberg PR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 Apr; 60(4):399-403. PubMed ID: 18178361
[TBL] [Abstract][Full Text] [Related]
23. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections.
Stein GE; Schooley S; Peloquin CA; Missavage A; Havlichek DH
J Antimicrob Chemother; 2007 Oct; 60(4):819-23. PubMed ID: 17673476
[TBL] [Abstract][Full Text] [Related]
24. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).
Appelbaum PC
Int J Antimicrob Agents; 2007 Nov; 30(5):398-408. PubMed ID: 17888634
[TBL] [Abstract][Full Text] [Related]
25. The first pediatric case of Staphylococcus aureus with heterogenous resistant to vancomycin endocarditis in Thailand.
Phongsamart W; Srifeungfung S; Tiensasitorn C; Vanprapar N; Chearskul S; Chokephaibulkit K
J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S264-8. PubMed ID: 16856450
[TBL] [Abstract][Full Text] [Related]
26. Increasing incidence of methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: reconsideration of empiric antimicrobial therapy.
Awad SS; Elhabash SI; Lee L; Farrow B; Berger DH
Am J Surg; 2007 Nov; 194(5):606-10. PubMed ID: 17936421
[TBL] [Abstract][Full Text] [Related]
27. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
Jacqueline C; Caillon J; Le Mabecque V; Miègeville AF; Hamel A; Bugnon D; Ge JY; Potel G
Antimicrob Agents Chemother; 2007 Sep; 51(9):3397-400. PubMed ID: 17591849
[TBL] [Abstract][Full Text] [Related]
28. Caution when reconsidering empiric antimicrobial therapy for methicillin-resistant Staphylococcus aureus skin and soft-tissue infections.
da Silva LV; Zavascki AP; de Souza MV; Marcadenti A
Am J Surg; 2008 Oct; 196(4):618-9. PubMed ID: 18809069
[No Abstract] [Full Text] [Related]
29. Management of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus: a survey of infectious diseases consultants.
Hageman JC; Liedtke LA; Sunenshine RH; Strausbaugh LJ; McDonald LC; Tenover FC;
Clin Infect Dis; 2006 Sep; 43(5):e42-5. PubMed ID: 16886141
[TBL] [Abstract][Full Text] [Related]
30. Vancomycin minimum inhibitory concentration as a predictor of mortality in methicillin-resistant Staphylococcus aureus bacteremia: a second look.
Porath AD; Brooks GD
Clin Infect Dis; 2008 May; 46(9):1483-4; author reply 1484-5. PubMed ID: 18419464
[No Abstract] [Full Text] [Related]
31. Comparison of both clinical features and mortality risk associated with bacteremia due to community-acquired methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus.
Wang JL; Chen SY; Wang JT; Wu GH; Chiang WC; Hsueh PR; Chen YC; Chang SC
Clin Infect Dis; 2008 Mar; 46(6):799-806. PubMed ID: 18266610
[TBL] [Abstract][Full Text] [Related]
32. Key considerations in the treatment of complicated staphylococcal infections.
Jones RN
Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():3-9. PubMed ID: 18226084
[TBL] [Abstract][Full Text] [Related]
33. Bacteremia due to clonally derived methicillin-resistant, gentamicin-susceptible isolates and methicillin-susceptible, gentamicin-resistant isolates of Staphylococcus aureus.
Daskalaki M; Otero JR; Sanz F; Chaves F
J Clin Microbiol; 2007 Oct; 45(10):3446-8. PubMed ID: 17699649
[TBL] [Abstract][Full Text] [Related]
34. In vitro susceptibility of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) to manufactured generic drugs compared with the brand vancomycin.
Fujimura S; Watanabe A; Fuse K; Kikuchi T; Gomi K; Tokue Y
Int J Antimicrob Agents; 2008 Apr; 31(4):391-2. PubMed ID: 18308516
[No Abstract] [Full Text] [Related]
35. Fatal bacteraemia caused by daptomycin-non-susceptible, vancomycin-intermediate, meticillin-resistant Staphylococcus aureus in a patient with chronic kidney disease.
Kuo CC; Wu VC; Huang YT; Liao CH; Hsueh PR
Int J Antimicrob Agents; 2009 Jan; 33(1):96-8. PubMed ID: 18790610
[No Abstract] [Full Text] [Related]
36. Childhood pustular psoriasis associated with Panton-Valentine leukocidin-producing Staphylococcus aureus.
Pouessel G; Ythier H; Carpentier O; Vachée A; Etienne J; Catteau B
Pediatr Dermatol; 2007; 24(4):401-4. PubMed ID: 17845166
[TBL] [Abstract][Full Text] [Related]
37. No decrease in clindamycin susceptibility despite increased use of clindamycin for pediatric community-associated methicillin-resistant Staphylococcus aureus skin infections.
Szczesiul JM; Shermock KM; Murtaza UI; Siberry GK
Pediatr Infect Dis J; 2007 Sep; 26(9):852-4. PubMed ID: 17721387
[TBL] [Abstract][Full Text] [Related]
38. Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes.
Hawkins C; Huang J; Jin N; Noskin GA; Zembower TR; Bolon M
Arch Intern Med; 2007 Sep; 167(17):1861-7. PubMed ID: 17893307
[TBL] [Abstract][Full Text] [Related]
39. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
40. MRSA bacteraemia.
Gould IM
Int J Antimicrob Agents; 2007 Nov; 30 Suppl 1():S66-70. PubMed ID: 17875386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
